flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76

flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 clinical (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators flow trial semaglutide kidney outcomes

Name: flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 clinical (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators flow trial semaglutide kidney outcomes
Brand: inmobiliariafranchi.com
SKU: 5955048517
Price: 20.65 USD
Availability: InStock
Rating: 4.225 (8 reviews)

SKU: 5955048517

4.2

USD20.65 USD70.65

Pay in 4 interest-free payments of $5.16 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 25 - Aug 30

Description

Ramaekers V, Blau N

Elevated blood concentrations of homocysteine have been considered for many years to be a risk factor for some chronic diseases, including cardiovascular disease and dementia (see Disease Prevention)